Your browser doesn't support javascript.
loading
Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
Tanabe, Kenji; Kobayashi, Shuichiro; Maezawa, Yuya; Ishihara, Kensaku; Inoue, Naoki; Izumi, Keita; Fujiwara, Motohiro; Toide, Masahiro; Yamamoto, Takanobu; Uehara, Sho; Araki, Saori; Inoue, Masaharu; Takazawa, Ryoji; Numao, Noboru; Ohtsuka, Yukihiro; Tanaka, Hajime; Yoshida, Soichiro; Fujii, Yasuhisa.
Afiliación
  • Tanabe K; Department of Urology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan.
  • Kobayashi S; Department of Urology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan. shu_kobayashi@saitama-med.jrc.or.jp.
  • Maezawa Y; Department of Urology, Tsuchiura Kyodo General Hospital, 1-1-4 Otsuno, Tsuchiura-shi, Ibaraki, 300-0028, Japan.
  • Ishihara K; Department of Urology, Soka Municipal Hospital, 1-21-2 Soka, Soka-shi, Saitama, 340-8560, Japan.
  • Inoue N; Department of Urology, JA Toride Medical Hospital, 1-1-2 Hongo, Toride-shi, Ibaraki, 302-0022, Japan.
  • Izumi K; Department of Urology, Dokkyo Medical University Saitama Medical Center, 50-1-2 Minamikoshigaya, Koshigaya-shi, Saitama, 343-8555, Japan.
  • Fujiwara M; Department of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
  • Toide M; Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 22-18-3 Honkomagome, Bunkyo-ku, Tokyo, 131-8677, Japan.
  • Yamamoto T; Department of Urology, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, 2-1-2 Nakazawa, Tama-shi, Tokyo, Japan.
  • Uehara S; Department of Urology, Showa General Hospital, 1-1-8 Hanakoganei, Kodaira-shi, Tokyo, Japan.
  • Araki S; Department of Urology, Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa-shi, Chiba, 272-8516, Japan.
  • Inoue M; Department of Urology, Saitama Prefectural Cancer Center, 780 Oaza-Komuro, Kitaadachi-gun-Ina-machi, Saitama, 362-0806, Japan.
  • Takazawa R; Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, 1-8-2 Minamiohtsuka, Toshima-ku, Tokyo, Japan.
  • Numao N; Department of Urology, Cancer Institute Hospital, 31-8-3 Ariake, Koto-ku, Tokyo, Japan.
  • Ohtsuka Y; Department of Urology, Japanese Red Cross Omori Hospital, 1-30-4 Chuo, Ota-ku, Tokyo, Japan.
  • Tanaka H; Department of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
  • Yoshida S; Department of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
  • Fujii Y; Department of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Int J Clin Oncol ; 29(9): 1302-1310, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38833113
ABSTRACT

BACKGROUND:

This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab.

METHODS:

This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model.

RESULTS:

During the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both p < 0.001) along with Eastern Cooperative Oncology Group Performance Status of ≥ 2 (both p < 0.001), presence of visceral metastasis (both p < 0.001), and hemoglobin of < 9.2 g/dL (p = 0.030 and p = 0.038). C-reactive protein of > 42 mg/L was a significant prognostic factor for OS (p = 0.001).

CONCLUSION:

The GRIm-score is an independent prognostic marker for survival outcomes in patients with platinum-refractory metastatic UC treated with pembrolizumab.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón